Details of the Drug Combination

General Information of Drug Combination (ID: DCKLEF1)

Drug Combination Name
Palbociclib Letrozole
Indication
Disease Entry Status REF
Neoplasms Phase 1 [1]
Component Drugs Palbociclib   DMD7L94 Letrozole   DMH07Y3
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Palbociclib
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Schizophrenia 6A20 Terminated [4]
Palbociclib Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 4 (CDK4) TT0PG8F CDK4_HUMAN Modulator [2]
Cyclin-dependent kinase 6 (CDK6) TTO0FDJ CDK6_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Palbociclib Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Palbociclib Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
Palbociclib Interacts with 151 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Response To Substance [10]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Increases Expression [7]
Kinetochore protein NDC80 homolog (NDC80) OTS7D306 NDC80_HUMAN Decreases Expression [7]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Decreases Expression [7]
Monocarboxylate transporter 5 (SLC16A4) OT1YXBKC MOT5_HUMAN Increases Expression [7]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [7]
Protein Mis18-beta (OIP5) OTI5C2DE MS18B_HUMAN Decreases Expression [7]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Increases Expression [7]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Decreases Expression [7]
Mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1) OT80DZMT BUB1_HUMAN Decreases Expression [7]
Hyaluronan mediated motility receptor (HMMR) OT4M0JTZ HMMR_HUMAN Decreases Expression [7]
Cell division control protein 45 homolog (CDC45) OT6NNLOD CDC45_HUMAN Decreases Expression [7]
Geminin (GMNN) OTDYKNIY GEMI_HUMAN Decreases Expression [7]
Glutaminase kidney isoform, mitochondrial (GLS) OTGOZG2M GLSK_HUMAN Increases Expression [11]
G2/mitotic-specific cyclin-B2 (CCNB2) OTIEXTDK CCNB2_HUMAN Decreases Expression [7]
Serine protease 23 (PRSS23) OT6DQAM1 PRS23_HUMAN Increases Expression [7]
Kinesin-like protein KIF20A (KIF20A) OTXOQHE0 KI20A_HUMAN Decreases Expression [7]
Chromosome-associated kinesin KIF4A (KIF4A) OT3UWL7D KIF4A_HUMAN Decreases Expression [7]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Increases Expression [7]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Decreases Expression [7]
G1/S-specific cyclin-E2 (CCNE2) OTBBUKQQ CCNE2_HUMAN Decreases Expression [12]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [13]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Activity [7]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Increases Expression [11]
Thymidine kinase, cytosolic (TK1) OTY5JFM1 KITH_HUMAN Decreases Expression [12]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Increases Expression [7]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [12]
SPARC (SPARC) OTPN90H0 SPRC_HUMAN Increases Expression [11]
Serine/threonine-protein kinase pim-1 (PIM1) OTWEKXTU PIM1_HUMAN Decreases Expression [13]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Decreases Expression [14]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Decreases Expression [12]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Decreases Expression [7]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Affects Localization [7]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Expression [7]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Decreases Expression [7]
Elastin (ELN) OTFSO7PG ELN_HUMAN Increases Expression [15]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Decreases Phosphorylation [16]
Stathmin (STMN1) OTDJ4RV0 STMN1_HUMAN Decreases Expression [7]
Cadherin-2 (CDH2) OTH0Y56P CADH2_HUMAN Increases Expression [7]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [17]
Lamin-B1 (LMNB1) OT100T3P LMNB1_HUMAN Decreases Expression [7]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Decreases Expression [7]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [18]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Activity [19]
High mobility group protein B2 (HMGB2) OTGEGAOK HMGB2_HUMAN Decreases Expression [7]
Retinoblastoma-like protein 1 (RBL1) OTDEBFYC RBL1_HUMAN Decreases Expression [17]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Increases Expression [20]
M-phase inducer phosphatase 1 (CDC25A) OTSLKKCO MPIP1_HUMAN Decreases Expression [7]
M-phase inducer phosphatase 3 (CDC25C) OTPQI71S MPIP3_HUMAN Decreases Expression [7]
Ribonucleoside-diphosphate reductase subunit M2 (RRM2) OTOB6J6R RIR2_HUMAN Decreases Expression [7]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Increases Phosphorylation [21]
Dual specificity protein kinase TTK (TTK) OTBY1Z5H TTK_HUMAN Decreases Expression [7]
DNA replication licensing factor MCM7 (MCM7) OT6FXC6K MCM7_HUMAN Decreases Expression [7]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases Expression [7]
Receptor-type tyrosine-protein kinase FLT3 (FLT3) OTMSRYMK FLT3_HUMAN Decreases Expression [13]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [20]
Flap endonuclease 1 (FEN1) OT6QGG7O FEN1_HUMAN Decreases Expression [7]
Replication factor C subunit 5 (RFC5) OTAD79RT RFC5_HUMAN Decreases Expression [7]
Cyclin-F (CCNF) OTJFVU43 CCNF_HUMAN Decreases Expression [7]
Lamina-associated polypeptide 2, isoform alpha (TMPO) OTL68EL4 LAP2A_HUMAN Decreases Expression [7]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Cleavage [16]
Ran-specific GTPase-activating protein (RANBP1) OTQE226K RANG_HUMAN Decreases Expression [11]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [12]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [19]
Histone H3-like centromeric protein A (CENPA) OT0NEJ4X CENPA_HUMAN Decreases Expression [7]
Centromere protein F (CENPF) OT7AG0SW CENPF_HUMAN Decreases Expression [7]
DNA primase small subunit (PRIM1) OTWWP8Y6 PRI1_HUMAN Decreases Expression [7]
Serine/threonine-protein kinase Nek2 (NEK2) OT1H27HO NEK2_HUMAN Decreases Expression [7]
Importin subunit alpha-1 (KPNA2) OTU7FOE6 IMA1_HUMAN Decreases Expression [7]
Kinesin-like protein KIF11 (KIF11) OTHRGLCQ KIF11_HUMAN Decreases Expression [7]
Serine/threonine-protein kinase PLK1 (PLK1) OTRZX45T PLK1_HUMAN Decreases Expression [7]
DNA polymerase epsilon subunit 2 (POLE2) OTAC9V6L DPOE2_HUMAN Decreases Expression [7]
Small ribosomal subunit protein uS14 (RPS29) OTCC1872 RS29_HUMAN Increases Expression [7]
Histone H4 (H4C1) OTB71W46 H4_HUMAN Decreases Expression [7]
G-protein-signaling modulator 2 (GPSM2) OT6RPMRM GPSM2_HUMAN Decreases Expression [7]
Centromere-associated protein E (CENPE) OTQ7AP04 CENPE_HUMAN Decreases Expression [7]
Kinesin-like protein KIF23 (KIF23) OTY850JC KIF23_HUMAN Decreases Expression [7]
Forkhead box protein M1 (FOXM1) OT5887KR FOXM1_HUMAN Decreases Expression [7]
Retinoblastoma-like protein 2 (RBL2) OTBQSOE6 RBL2_HUMAN Decreases Phosphorylation [22]
Tastin (TROAP) OTC8CE0R TROAP_HUMAN Decreases Expression [7]
Cell division cycle protein 20 homolog (CDC20) OTCOEZRV CDC20_HUMAN Decreases Expression [7]
Laminin subunit beta-3 (LAMB3) OTFPU6W8 LAMB3_HUMAN Increases Expression [7]
Laminin subunit gamma-2 (LAMC2) OTJMTM72 LAMC2_HUMAN Increases Expression [7]
DNA polymerase alpha subunit B (POLA2) OTTWQ73N DPOA2_HUMAN Decreases Expression [7]
Transcription factor E2F2 (E2F2) OTO75RM7 E2F2_HUMAN Decreases Expression [7]
Max dimerization protein 4 (MXD4) OTUCXFRO MAD4_HUMAN Increases Expression [7]
Maternal embryonic leucine zipper kinase (MELK) OTEY2UQA MELK_HUMAN Decreases Expression [7]
PCNA-associated factor (PCLAF) OTMVIOUU PAF15_HUMAN Decreases Expression [7]
Condensin complex subunit 1 (NCAPD2) OT8VGE2O CND1_HUMAN Decreases Expression [7]
Kinesin-like protein KIF14 (KIF14) OTXHT4JM KIF14_HUMAN Decreases Expression [7]
Disks large-associated protein 5 (DLGAP5) OTWCN39U DLGP5_HUMAN Decreases Expression [7]
SCL-interrupting locus protein (STIL) OT9799VN STIL_HUMAN Decreases Expression [7]
Histone-lysine N-methyltransferase EZH2 (EZH2) OTIEHTKW EZH2_HUMAN Decreases Expression [7]
Cyclin-dependent kinase inhibitor 3 (CDKN3) OTBE3H07 CDKN3_HUMAN Decreases Expression [7]
Laminin subunit alpha-3 (LAMA3) OTFME7HT LAMA3_HUMAN Increases Expression [7]
Centrosomal protein of 55 kDa (CEP55) OTGSG2PA CEP55_HUMAN Decreases Expression [7]
Borealin (CDCA8) OT17D55D BOREA_HUMAN Decreases Expression [7]
PHD finger protein 19 (PHF19) OTF6RUCR PHF19_HUMAN Decreases Expression [7]
Proline/serine-rich coiled-coil protein 1 (PSRC1) OT7MDJMN PSRC1_HUMAN Decreases Expression [7]
Protein aurora borealis (BORA) OTV2ZPKP BORA_HUMAN Decreases Expression [7]
Interleukin-20 receptor subunit beta (IL20RB) OTHFXK95 I20RB_HUMAN Increases Expression [7]
Protein MCM10 homolog (MCM10) OTV0O3JN MCM10_HUMAN Decreases Expression [7]
Suppressor APC domain-containing protein 2 (SAPCD2) OTXS0EXM SAPC2_HUMAN Decreases Expression [7]
Condensin-2 complex subunit G2 (NCAPG2) OTZYENKO CNDG2_HUMAN Decreases Expression [7]
Cytoskeleton-associated protein 2-like (CKAP2L) OT4T73GG CKP2L_HUMAN Decreases Expression [7]
Kinetochore protein Spc24 (SPC24) OT1HVYV4 SPC24_HUMAN Decreases Expression [7]
Holliday junction recognition protein (HJURP) OTWMV16B HJURP_HUMAN Decreases Expression [7]
Protein DENND6B (DENND6B) OTZ006UD DEN6B_HUMAN Increases Expression [7]
DEP domain-containing protein 1B (DEPDC1B) OTMVFOT1 DEP1B_HUMAN Decreases Expression [7]
Retinol dehydrogenase 5 (RDH5) OTYBZHCC RDH5_HUMAN Increases Expression [7]
RAD51-associated protein 1 (RAD51AP1) OTXM7UTD R51A1_HUMAN Decreases Expression [7]
Sororin (CDCA5) OTZLCQ5U CDCA5_HUMAN Decreases Expression [7]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Decreases Expression [7]
Proline-rich protein 11 (PRR11) OT2JJ08Z PRR11_HUMAN Decreases Expression [7]
Lymphokine-activated killer T-cell-originated protein kinase (PBK) OT5Z27TW TOPK_HUMAN Decreases Expression [7]
Tetratricopeptide repeat protein 14 (TTC14) OTMTYOPF TTC14_HUMAN Increases Expression [7]
Serine protease FAM111A (FAM111A) OTVLARLG F111A_HUMAN Decreases Expression [7]
Cell division cycle-associated protein 3 (CDCA3) OTUI8QK3 CDCA3_HUMAN Decreases Expression [7]
Kinesin-like protein KIF2C (KIF2C) OTJ8G3NP KIF2C_HUMAN Decreases Expression [7]
BRCA1-associated RING domain protein 1 (BARD1) OTTC0Z9Y BARD1_HUMAN Decreases Expression [7]
Condensin complex subunit 3 (NCAPG) OT1AI9EO CND3_HUMAN Decreases Expression [7]
Protein PIMREG (PIMREG) OTKC8T3E PIMRE_HUMAN Decreases Expression [7]
Kinesin-like protein KIFC1 (KIFC1) OTNQDS00 KIFC1_HUMAN Decreases Expression [7]
Nucleolar and spindle-associated protein 1 (NUSAP1) OT85HIJ5 NUSAP_HUMAN Decreases Expression [7]
Rac GTPase-activating protein 1 (RACGAP1) OTQE8IEH RGAP1_HUMAN Decreases Expression [7]
DNA replication factor Cdt1 (CDT1) OTVY53VG CDT1_HUMAN Decreases Expression [7]
Protein-serine O-palmitoleoyltransferase porcupine (PORCN) OT79GAY2 PORCN_HUMAN Increases Expression [7]
Protein FAM83D (FAM83D) OTQWZ1UO FA83D_HUMAN Decreases Expression [7]
Fanconi anemia group E protein (FANCE) OTKRPBW1 FANCE_HUMAN Decreases Expression [11]
Kinetochore protein Spc25 (SPC25) OTCAS0OH SPC25_HUMAN Decreases Expression [7]
Inner centromere protein (INCENP) OT9HFRYK INCE_HUMAN Decreases Expression [7]
Anillin (ANLN) OTXJY54C ANLN_HUMAN Decreases Expression [7]
Kinesin-like protein KIF15 (KIF15) OTJRJEXL KIF15_HUMAN Decreases Expression [7]
Centromere protein M (CENPM) OTYK9KOX CENPM_HUMAN Decreases Expression [7]
Structural maintenance of chromosomes protein 4 (SMC4) OTEJE6AG SMC4_HUMAN Decreases Expression [7]
Fanconi anemia group I protein (FANCI) OTW8E3SC FANCI_HUMAN Decreases Expression [7]
Histone chaperone ASF1B (ASF1B) OTKXX12I ASF1B_HUMAN Decreases Expression [7]
Protein downstream neighbor of Son (DONSON) OTN5HE0W DONS_HUMAN Decreases Expression [7]
Carboxypeptidase A4 (CPA4) OT66MP0F CBPA4_HUMAN Increases Expression [7]
F-box only protein 5 (FBXO5) OTTR957W FBX5_HUMAN Decreases Expression [7]
Targeting protein for Xklp2 (TPX2) OTWLJYH0 TPX2_HUMAN Decreases Expression [7]
Exonuclease 1 (EXO1) OTI87RS5 EXO1_HUMAN Decreases Expression [7]
DNA replication complex GINS protein PSF2 (GINS2) OT974IYI PSF2_HUMAN Decreases Expression [7]
Small kinetochore-associated protein (KNSTRN) OTYA7UXS SKAP_HUMAN Decreases Expression [7]
Transforming acidic coiled-coil-containing protein 3 (TACC3) OTRNEZTA TACC3_HUMAN Decreases Expression [11]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Response To Substance [23]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B) OTAG24N1 CDN2B_HUMAN Decreases Response To Substance [10]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Decreases Response To Substance [23]
G1/S-specific cyclin-E1 (CCNE1) OTLD7UID CCNE1_HUMAN Decreases Response To Substance [23]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Increases Response To Substance [23]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Response To Substance [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 151 DOT(s)
Indication(s) of Letrozole
Disease Entry ICD 11 Status REF
Estrogen-receptor positive breast cancer N.A. Approved [5]
Hormonally-responsive breast cancer 2C60-2C65 Approved [6]
Letrozole Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [24]
------------------------------------------------------------------------------------
Letrozole Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [25]
Aromatase (CYP19A1) DEQX145 CP19A_HUMAN Metabolism [26]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [27]
------------------------------------------------------------------------------------
Letrozole Interacts with 18 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Activity [28]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Oxidation [29]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Increases Oxidation [29]
Adenylate kinase isoenzyme 1 (AK1) OT614AR3 KAD1_HUMAN Increases ADR [30]
Dickkopf-related protein 1 (DKK1) OTRDLUSP DKK1_HUMAN Increases Expression [31]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Increases Expression [32]
Lutropin subunit beta (LHB) OT5GBOVJ LSHB_HUMAN Increases Expression [32]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Decreases Expression [33]
Leukemia inhibitory factor (LIF) OTO46S5S LIF_HUMAN Increases Expression [31]
Gap junction alpha-1 protein (GJA1) OTT94MKL CXA1_HUMAN Decreases Expression [34]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [35]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Decreases Expression [35]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [36]
Leukemia inhibitory factor receptor (LIFR) OT36W9O5 LIFR_HUMAN Increases Expression [31]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [33]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [35]
Lanosterol 14-alpha demethylase (CYP51A1) OTAYHG9C CP51A_HUMAN Decreases Activity [37]
Fibroblast growth factor 22 (FGF22) OTVIX6J0 FGF22_HUMAN Increases Expression [31]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Breast Neoplasms DCKM9VL N. A. Phase 1 [38]
Anatomic Stage I Breast Cancer AJCC v8 DCMXE98 N. A. Phase 1 [39]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01684215) A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
3 ClinicalTrials.gov (NCT01723774) PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer. U.S. National Institutes of Health.
4 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
5 Letrozole FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5209).
7 Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
8 Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
9 Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105.
10 p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012 Jul;14(7):870-81. doi: 10.1093/neuonc/nos114. Epub 2012 Jun 18.
11 Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.
12 Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38.
13 Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20.
14 Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. Molecules. 2014 Feb 17;19(2):2077-88. doi: 10.3390/molecules19022077.
15 Retinoblastoma protein modulates the inverse relationship between cellular proliferation and elastogenesis. J Biol Chem. 2011 Oct 21;286(42):36580-91. doi: 10.1074/jbc.M111.269944. Epub 2011 Aug 31.
16 CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 2012 Jul 15;11(14):2747-55. doi: 10.4161/cc.21127. Epub 2012 Jul 15.
17 Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010 May;138(5):1920-30. doi: 10.1053/j.gastro.2010.01.007. Epub 2010 Jan 25.
18 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
19 Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood. 2007 Sep 15;110(6):2075-83. doi: 10.1182/blood-2007-02-071266. Epub 2007 May 30.
20 Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010 Jul 15;29(28):4018-32. doi: 10.1038/onc.2010.154. Epub 2010 May 17.
21 CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Res. 2014 Jul 15;74(14):3947-58. doi: 10.1158/0008-5472.CAN-13-2923. Epub 2014 Jul 1.
22 Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia. 2016 Jan;30(1):86-93. doi: 10.1038/leu.2015.185. Epub 2015 Jul 15.
23 Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 2011 Mar 15;17(6):1591-602. doi: 10.1158/1078-0432.CCR-10-2307. Epub 2011 Jan 28.
24 Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
25 Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol. 2009 Oct;64(5):867-75.
26 Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer. 1999 Feb;35(2):208-13.
27 Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Res Treat. 2018 Nov;172(2):371-379.
28 Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
29 Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2009 Nov;39(11):795-802. doi: 10.3109/00498250903171395.
30 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
31 Clomiphene citrate versus letrozole: molecular analysis of the endometrium in women with polycystic ovary syndrome. Fertil Steril. 2011 Oct;96(4):1051-6. doi: 10.1016/j.fertnstert.2011.07.1092.
32 Aromatase inhibition, testosterone, and seizures. Epilepsy Behav. 2004 Apr;5(2):260-3. doi: 10.1016/j.yebeh.2003.12.001.
33 Aromatase inhibitors: cellular and molecular effects. J Steroid Biochem Mol Biol. 2005 May;95(1-5):83-9. doi: 10.1016/j.jsbmb.2005.04.010.
34 Inhibition of estrogen receptor reduces connexin 43 expression in breast cancers. Toxicol Appl Pharmacol. 2018 Jan 1;338:182-190. doi: 10.1016/j.taap.2017.11.020. Epub 2017 Nov 24.
35 Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005 Jul 15;11(14):5319-28. doi: 10.1158/1078-0432.CCR-04-2402.
36 Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat. 2010 Nov;124(1):79-88. doi: 10.1007/s10549-009-0714-5. Epub 2010 Jan 7.
37 Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles. Toxicology. 2006 Nov 10;228(1):24-32. doi: 10.1016/j.tox.2006.08.007. Epub 2006 Aug 12.
38 ClinicalTrials.gov (NCT01740427) A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
39 ClinicalTrials.gov (NCT03774472) Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer